While most studies use as criteria for defining MHO less than 2 conditions of metabolic syndrome (MS), others use a more strict definition, i.e., the absence of type 2 diabetes, dyslipidemia, and hypertension [4,5,6], and some include also markers of homeostasis model assessment of insulin resistance (HOMA-IR) and systemic inflammation markers such as C reactive protein (CRP) [7,8,9]. Here, CRP is linked to myeloid sarcoma.